journal article·2024-01-16

Nanoparticles Based on Natural Lipids Reveal Extent of Impacts of Designed Physical Characteristics on Biological Functions

Niko Kimura, Yoko Tanaka, Yoko Yamanishi, Akiko Takahashi, Shinya Sakuma

ACS Nano· Volume 18· Issue 2
Publisher page

Abstract

Nanoparticles based on lipids (LNPs) are essential in pharmaceuticals and intercellular communication, and their design parameters span a diverse range of molecules and assemblies. In bridging the gap in insight between extracellular vesicles (EVs) and synthetic LNPs, one challenge is understanding their in-cell/in-body behavior when simultaneously assessing more than one physical characteristic. Herein, we demonstrate comprehensive evaluation of LNP behavior by using LNPs based on natural lipids (N-LNPs) with designed physical characteristics: size tuned using microfluidic methods, surface fluidity designed based on EV components, and stiffness tuned using biomolecules. We produce 12 types of N-LNPs having different physical characteristics─two sizes, three membrane fluidities, and two stiffnesses for in vitro evaluation─and evaluate cellular uptake vitality and endocytic pathways of N-LNPs based on the physical characteristics of N-LNPs. To reveal the extent of the impact of the predesigned physical characteristics of N-LNPs on cellular uptakes in vivo, we also carried out animal experiments with four types of N-LNPs having different sizes and fluidities. The use of N-LNPs has helped to clarify the extent of the impact of inextricably related, designed physical characteristics on transportation and provided a bidirectional guidepost for the streamlined design and understanding of the biological functions of LNPs.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Extracellular vesicles in disease · RNA Interference and Gene Delivery · Lipid Membrane Structure and Behavior

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Applied Chemistry, Faculty of Engineering, Kyushu University, Fukuoka 819-0395, Japan

Division of Cellular Senescence, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan

Department of Mechanical Engineering, Faculty of Engineering, Kyushu University, Fukuoka 819-0395, Japan

Cancer Cell Communication Project, NEXT-Ganken Program, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan

Funding

Moonshot Research and Development Program · Japan Society for the Promotion of Science · Foundation for Promotion of Material Science and Technology of Japan · Co-Create Knowledge for Pharma Innovation with Takeda

References (74)

Show source-provided references
1. 10.1038/nature2060710.1038/nature20607 ↗
2. 10.1126/sciadv.abe008310.1126/sciadv.abe0083 ↗
3. 10.1126/science.abm555110.1126/science.abm5551 ↗
4. 10.1016/j.cell.2020.07.02410.1016/j.cell.2020.07.024 ↗
5. 10.1038/s41586-023-06114-410.1038/s41586-023-06114-4 ↗
6. 10.1126/science.abm084010.1126/science.abm0840 ↗
7. 10.1038/ncomms1528710.1038/ncomms15287 ↗
8. 10.3390/jcm908238010.3390/jcm9082380 ↗
9. 10.3402/jev.v4.2853310.3402/jev.v4.28533 ↗
10. 10.1073/pnas.152123011310.1073/pnas.1521230113 ↗
11. 10.3402/jev.v4.2703110.3402/jev.v4.27031 ↗
12. 10.1126/sciadv.aaz698010.1126/sciadv.aaz6980 ↗
13. 10.1038/s41565-017-0012-z10.1038/s41565-017-0012-z ↗
14. 10.1126/sciadv.abg666610.1126/sciadv.abg6666 ↗
15. 10.1126/science.abb892310.1126/science.abb8923 ↗
16. 10.1038/s41467-021-27493-010.1038/s41467-021-27493-0 ↗
17. 10.1056/NEJMoa210745410.1056/NEJMoa2107454 ↗
18. 10.1126/sciadv.abc945010.1126/sciadv.abc9450 ↗
19. 10.1038/s41565-020-0669-610.1038/s41565-020-0669-6 ↗
20. 10.1038/s41467-022-31993-y10.1038/s41467-022-31993-y ↗
21. 10.1016/j.jconrel.2022.03.04610.1016/j.jconrel.2022.03.046 ↗
22. 10.1038/nnano.2011.16610.1038/nnano.2011.166 ↗
23. 10.1126/sciadv.aaz431610.1126/sciadv.aaz4316 ↗
24. 10.1038/s41467-020-16248-y10.1038/s41467-020-16248-y ↗
25. 10.1016/S0022-2836(65)80093-610.1016/S0022-2836(65)80093-6 ↗
26. 10.1021/ja031803010.1021/ja0318030 ↗
27. 10.1021/ja301621z10.1021/ja301621z ↗
28. 10.1021/acsomega.8b0034110.1021/acsomega.8b00341 ↗
29. 10.1038/s41467-022-34750-310.1038/s41467-022-34750-3 ↗
30. 10.1016/j.jconrel.2016.05.05910.1016/j.jconrel.2016.05.059 ↗
31. 10.1002/adma.20221142010.1002/adma.202211420 ↗
32. 10.1097/FJC.000000000000060610.1097/FJC.0000000000000606 ↗
33. 10.1126/sciadv.abf439810.1126/sciadv.abf4398 ↗
34. 10.1021/acs.nanolett.5b0249710.1021/acs.nanolett.5b02497 ↗
35. 10.1038/s41467-020-14527-210.1038/s41467-020-14527-2 ↗
36. 10.1073/pnas.210482611810.1073/pnas.2104826118 ↗
37. 10.1038/s41467-017-02588-910.1038/s41467-017-02588-9 ↗
38. 10.1016/j.apsb.2019.02.01010.1016/j.apsb.2019.02.010 ↗
39. 10.1038/s41556-018-0040-410.1038/s41556-018-0040-4 ↗
40. 10.1042/bj2003159410.1042/bj20031594 ↗
41. 10.1529/biophysj.105.06943510.1529/biophysj.105.069435 ↗
42. 10.1021/acs.jpcb.5b0660410.1021/acs.jpcb.5b06604 ↗
43. 10.1529/biophysj.104.05471810.1529/biophysj.104.054718 ↗
44. 10.1073/pnas.200480711710.1073/pnas.2004807117 ↗
45. 10.1039/C9NR09347H10.1039/C9NR09347H ↗
46. 10.1016/j.addr.2020.03.00210.1016/j.addr.2020.03.002 ↗
47. 10.1038/s41565-019-0591-y10.1038/s41565-019-0591-y ↗
48. International Council on Harmonisation (ICH). ICH Harmonized Guideline on Impurities: Guideline for Residual Solvents Q3C(R8), 2021. https://database.ich.org/sites/default/files/ICH_Q3C-R8_Guideline_Step4_2021_0422.pdf (accessed Nov 28, 2022).
49. 10.1016/j.plipres.2017.03.00110.1016/j.plipres.2017.03.001 ↗
50. 10.18632/oncotarget.867810.18632/oncotarget.8678 ↗
51. 10.1021/acs.langmuir.0c0026210.1021/acs.langmuir.0c00262 ↗
52. 10.1371/journal.pone.004748010.1371/journal.pone.0047480 ↗
53. 10.1194/jlr.M08855910.1194/jlr.M088559 ↗
54. 10.1186/s12943-022-01509-910.1186/s12943-022-01509-9 ↗
55. 10.1038/s41565-021-00931-210.1038/s41565-021-00931-2 ↗
56. 10.1038/nature1575610.1038/nature15756 ↗
57. 10.1080/20013078.2020.172238510.1080/20013078.2020.1722385 ↗
58. 10.1038/s41467-020-20500-w10.1038/s41467-020-20500-w ↗
59. 10.1021/acsabm.0c0151910.1021/acsabm.0c01519 ↗
60. 10.1007/s11095-017-2097-310.1007/s11095-017-2097-3 ↗
61. 10.1021/acsnano.8b0151610.1021/acsnano.8b01516 ↗
62. 10.3402/jev.v4.2968510.3402/jev.v4.29685 ↗
63. 10.1038/s41586-021-04234-310.1038/s41586-021-04234-3 ↗
64. 10.1073/pnas.210925611810.1073/pnas.2109256118 ↗
65. 10.1073/pnas.211627111910.1073/pnas.2116271119 ↗
66. 10.1021/acsnano.0c1006410.1021/acsnano.0c10064 ↗
67. 10.1039/D0BM01609H10.1039/D0BM01609H ↗
68. 10.1073/pnas.140116511110.1073/pnas.1401165111 ↗
69. 10.1016/j.dmpk.2021.10042410.1016/j.dmpk.2021.100424 ↗
70. 10.1021/acs.nanolett.2c0323410.1021/acs.nanolett.2c03234 ↗
71. 10.1038/nnano.2015.34210.1038/nnano.2015.342 ↗
72. 10.1002/anie.20201326510.1002/anie.202013265 ↗
73. Baiceanu A. · Farmacia · 2018 · 66 · 26
74. 10.1073/pnas.080161310510.1073/pnas.0801613105 ↗